Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: E. Charters who wrote (91753)	12/19/2011 2:20:19 PM
From: Postman	Read Replies (1) \| Respond to of 233883

""""Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines. Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response. For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer. Positive interim results from that study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012." ------------------------------------------------ http://www.fiercevaccines.com/special-reports/10-promising-therapeutic-vaccines/ae37-10-promising-therapeutic-vaccine It seems to be having a good effect in Phase 2 trials----- -------------------- On another alternate cancer treatment note: burzynskiclinic.com has some great alternate treatments that have been developed through years of research as well- and he fought off the industry negativity and big pharma piracy to get them through and hold on to his patents- a remarkable story